Effectiveness of Autologous Platelet-Rich Plasma Therapy in Women with Repeated Implantation Failure: A Randomized Clinical Trial

Platelet-rich plasma (PRP) therapy has been shown to enhance tissue regeneration by expressing severalcytokines and growth factors (GFs). This study investigated the effect of intrauterine infusion of PRP as a noninvasiveautologous GF on pregnancy outcomes in women with repeated implantation failure. This randomized clinical trial was conducted to compare the pregnancy rates between twogroups of women who were candidates for the frozen-thawed embryo transfer with a history of two or more implantationfailures. The PRP group (n=33) was treated with hormone replacement therapy+0.5 cc to 1 cc PRP infusedinto the uterine cavity two days before the embryo transfer. The control group (n=33) was only treated with hormonereplacement therapy. The endometrial preparation process was done similarly in both groups. The chemical, clinical,and ongoing pregnancy, and implantation rates were compared between the two groups. Our results showed that the chemical pregnancy rate was not statistically higher in the PRP group in comparisonwith the control group (36.4 vs. 24.2%). In addition, the clinical pregnancy, ongoing pregnancy, and implantationrates were higher in the PRP group than the control group; however, the difference between the two groups was notstatistically significant. Administration of intrauterine PRP before embryo transfer in women with repeated implantation failure(RIF) does not affect assisted reproductive technology (ART) outcomes (registration number: IRCT2016090728950N3).